Saturday 17 October 2026 Export PLUR’s income statement to Excel — free account

Pluri Inc.

Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025. In the quarter to June 2026, revenue fell 15.8%, EPS grew 48.0%, free cash flow grew 25.0% and total debt rose 3.43%, each against the same quarter a year earlier.

0.93 0.01 −1.06%

Follow PLUR

Alert me

Market cap: $11.9M
P/E: 0.0×
Fwd P/E: −0.8×
Dividend yield: —
F-score: 1/9
Altman Z: −30.41
Beneish M: −4.29
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.87%

Capital & Financial Ratios $m

Market Cap 11.86

Revenue 1.02

Net Income (25.37)

Free Cash Flow (20.20)

Net Debt 20.39

Current Ratio 0.27

Debt/Equity (1.62)

P/E ratio 0.00

Fwd P/E (0.83)

P/S ratio 8.92

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth 901.97%

Next 5Y EPS Growth 33.58%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.07%

10-year low 10-year high

EV/Sales against its own 10 years 14.90%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	2026
Cash	40	30	21	8
Receivables	1	0	0	0
Inventory	—	—	—	—
Other	—	—	—	—
	41	31	22	9

	2023	2024	2025	2026
Payables	3	2	2	2
ST’ Debt	1	—	27	27
Other	3	0	0	0
	6	4	32	33

Compound Annual Growth %

	10y	5y	3y
Sales	10.36%	113.32%	52.41%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	0	0	0	0	1
’25	0	0	0	0	1
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	—	—	0	—	0
’20	—	0	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(5)	(5)	(5)	(4)	(20)
’25	(4)	(5)	(4)	(5)	(18)
’24	(6)	(4)	(4)	(4)	(18)
’23	(8)	(6)	(6)	(3)	(23)
’22	(9)	(10)	(9)	(8)	(37)
’21	(6)	(8)	(7)	(10)	(31)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(6)	(6)	(5)	(4)	(20)
’25	(4)	(5)	(5)	(6)	(20)
’24	(6)	(4)	(4)	(4)	(18)
’23	(8)	(6)	(6)	(3)	(23)
’22	(9)	(10)	(9)	(9)	(37)
’21	(6)	(8)	(7)	(10)	(31)

Fiscal quarters ending in the months shown.

EPS $

	Sep	Dec	Mar	Jun	Year
’26	—	—	—	—	—
’26	(0.65)	(0.71)	(0.55)	(0.54)	(2.44)
’25	(1.08)	(0.53)	(0.94)	(1.04)	(3.56)
’24	(0.96)	(0.96)	(1.01)	(1.09)	(3.99)
’23	(1.52)	(1.92)	(1.52)	(1.20)	(6.24)
’22	(2.88)	(2.72)	(2.48)	(2.24)	(10.24)
’21	(2.66)	(3.92)	(3.84)	(3.68)	(14.16)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	83.20	52.80	24.88	22.56	11.44	5.20	3.44	4.07	2.82	0.85	Analyst estimates 2027–2029 Powerpack
	High	169.60	132.00	95.20	106.32	79.12	18.16	11.60	8.48	7.13	3.90
People
People	Employees	183	180	165	158	162	159	134	118	142	113
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.01
Income, $m
Income, $m	Revenue	—	0	0	0	—	0	0	0	1	1
	Gross margin, %	0.00	96.00	96.30	100.00	0.00	100.00	96.86	98.77	48.95	44.59
	EBT	(28)	(26)	(35)	(29)	(50)	(41)	(29)	(21)	(23)	(25)
	EBT margin, %	0.00	(52,252.00)	(65,383.33)	(126,747.83)	0.00	(17,681.20)	(10,065.16)	(6,547.24)	(1,740.64)	(2,499.41)
	Net income	(28)	(26)	(35)	(29)	(50)	(41)	(29)	(21)	(23)	(25)
	Depreciation	2	2	2	2	1	1	0	0	0	1
Per share, $
Per share, $	Revenue	0.00	0.04	0.04	0.01	0.00	0.06	0.06	0.06	0.21	0.10
	Earnings	(25.60)	(20.00)	(21.36)	(12.37)	(14.16)	(10.24)	(6.24)	(3.99)	(3.56)	(2.44)
	Cash flow	(19.77)	(16.15)	(19.11)	(11.59)	(8.80)	(9.07)	(4.99)	(3.44)	(2.87)	(2.01)
	Capex	(0.32)	(0.26)	(0.15)	(0.12)	(0.11)	(0.07)	(0.06)	(0.06)	(0.26)	(0.06)
	Free cash flow	(20.09)	(16.41)	(19.26)	(11.71)	(8.90)	(9.14)	(5.05)	(3.50)	(3.13)	(2.07)
	Book value	27.68	21.54	14.15	24.66	16.26	8.00	3.34	1.03	(0.14)	(1.79)
	Shares, m	1	1	2	2	4	4	5	5	6	10
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	0.00
	P/S	—	45.69	699.65	2,089.09	—	128.98	102.18	92.58	23.48	20.04
	P/B	—	4.64	3.33	2.87	—	1.23	1.92	5.57	0.00	0.00
	EV/Sales	—	35.13	465.06	1,507.87	—	19.28	45.44	75.50	46.83	40.12
	EV/FCF	—	(4.68)	(1.63)	(4.36)	—	(0.16)	(0.56)	(1.34)	(3.16)	(2.02)
Cash, $m
Cash, $m	Operating cash flow	(22)	(21)	(29)	(26)	(31)	(37)	(23)	(18)	(18)	(20)
	Capex	0	0	0	0	0	0	0	0	(2)	(1)
	Free cash flow	(22)	(22)	(30)	(27)	(31)	(37)	(23)	(18)	(20)	(20)
Balance, $m
Balance, $m	Working capital	24	23	18	40	56	51	36	27	(10)	(24)
	Total debt	—	—	—	2	24	22	24	24	27	28
	Net debt	(27)	(31)	(24)	(45)	(41)	(34)	(16)	(6)	6	20
	Shareholders’ equity	30	29	22	56	57	32	15	5	(1)	(17)
Returns, %
Returns, %	ROA	(66.64)	(68.31)	(100.49)	(60.21)	(62.70)	(51.04)	(47.65)	(46.25)	(57.75)	(74.95)
	ROIC	(488.34)	0.00	0.00	(162.36)	(196.66)	0.00	0.00	0.00	(257.19)	(526.92)
	ROE	(81.32)	(88.93)	(140.31)	(74.82)	(88.06)	(92.33)	(119.28)	(201.67)	(992.66)	260.35

Negative figures in brackets.

All 10 years →

Fiscal years to Jun 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CASIF CASI Pharmaceuticals Inc.	$12.4M	— (loss-making)	— (loss-making)	−45.93% (below 0%: shrinking)	n/m	−23,251.69% (below 0%: shrinking)	51.14%	(147.67%)	Compare
AEON AEON Biopharma, Inc.	$12.1M	— (loss-making)	—	—	n/m	−76.85% (below 0%: shrinking)	—	0.00%	Compare
ASBP Aspire-Lakewood Holdings, Inc.	$12.1M	0.2×	—	—	n/m	−85.54% (below 0%: shrinking)	(47.70%)	(4,244.37%)	Compare
ACTU Actuate Therapeutics, Inc.	$12.0M	— (loss-making)	—	—	n/m	−5.54% (below 0%: shrinking)	—	0.00%	Compare
PLUR Pluri Inc.	$11.9M	— (loss-making)	— (loss-making)	−15.83% (below 0%: shrinking)	n/m	+25.03% (above 0%: growing)	58.51%	(1,655.52%)
INAB IN8bio, Inc.	$11.7M	— (loss-making)	—	—	n/m	−1.30% (below 0%: shrinking)	0.00%	0.00%	Compare
ENSC Ensysce Biosciences, Inc.	$11.6M	— (loss-making)	— (loss-making)	−15.10% (below 0%: shrinking)	n/m	+27.50% (above 0%: growing)	100.00%	(221.28%)	Compare
PASG Passage Bio, Inc.	$11.6M	— (loss-making)	—	—	n/m	−59.81% (below 0%: shrinking)	0.00%	0.00%	Compare
PTN Palatin Technologies, Inc.	$11.6M	— (loss-making)	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
Median of peers	$11.8M	—	—	−15.10%	—	−32.67%	25.57%	(73.83%)

All 614 Biotechnology stocks →

Pluri Inc. (PLUR) key facts

Concern: Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025.
Pluri Inc. (PLUR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, PLUR traded at $0.93, a market capitalization of $11.9 million.
Return on equity was 260.4% and debt-to-equity -1.62.
Its Piotroski F-score is 1 out of 9 and its Altman Z-score is −30.41 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.